Profile: Affimed NV (AFMD.OQ)
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. The Company's research and development pipeline consists of AFM13, AFM11, AFM21, AFM22, AFM24, TandAb and Trispecific Abs. The Company generates its pipeline of product candidates from three platform technologies based on its tetravalent antibody architecture characterized by four binding domains, creating bispecific NK-cell and T-cell TandAbs (binding to two different targets) and Trispecific Abs (binding to three different targets). Its bispecific antibodies, TandAbs, are designed to direct and establish a bridge between either Natural Killer (NK)-cells or T-cells and cancer cells. The Company's TandAbs brings NK-cells or T-cells into proximity and triggers a signal cascade that leads to the destruction of cancer cells.
The Company's AFM13 is a first-in-class NK-cell TandAb that it has engineered to bind with high affinity to CD30 expressing tumor cells while binding to CD16A surface proteins to activate NK-cells. AFM13 is intravenously administered in order to recruit NK-cells in peripheral blood and transport them to the tumor by binding to CD30. The Company has started recruitment for Phase IIa clinical trial of AFM13 in patients with Hodgkin Lymphoma (HL). AFM11 is a T-cell TandAb that it has engineered to bind with high affinity to both the CD19 receptor on certain tumor cells and CD3, a component of the T-cell receptor complex. AFM21 is in preclinical development. The Company has initiated a Phase I clinical trial of AFM11 in patients with non-Hodgkin Lymphoma (NHL). AFM21 selectively binds Epidermal Growth Factor Receptor variant III (EGFRvIII), a receptor that appears to be highly specific for certain solid tumors and is prominent in a significant proportion of patients with glioblastoma, hormone refractory prostate cancers, and head and neck cancers. AFM21 also binds CD3, directing T-cells to destroy tumor cells that carry EGFRvIII.
The Company has initiated development of an EGFRvIII/CD16A NK-cell TandAb, AFM22. AFM22, which is an EGFRvIII/CD16A NK-cell TandAb is in preclinical development. AFM24 is an additional CD16A NK-cell TandAb targeting a validated solid tumor target, EGFR-wild type. AFM24 has been engineered and characterized preclinically. The Company's markets include HL and CD30-positive Malignancies, NHL, CD19-positive Malignancies and EGFRvIII-positive Malignancies. The Company supports an investigator-sponsored Phase Ib/IIa clinical trial of AMF13 in patients with CD30+ lymphoma. It is developing Trispecific Abs for various undisclosed targets, which are at a discovery stage to be developed for indications, such as multiple myeloma (MM). The Company is developing a CD33/CD3-specific T-cell TandAb to treat acute myeloid leukemia (AML).
The Company competes with Innate Pharma, Novartis AG, Celgene, MABLife, Pfizer, Gilead Sciences, Amgen, MacroGenics, Juno Therapeutics, Bellicum, Cellectis, Seattle Genetics, Kite Pharma and Regeneron.
Im Neuenheimer Feld 582